Airsupra Could Help Revive AstraZeneca's Respiratory Fortunes

Will Soften Impact Of Declining Symbicort Sales

The US Food and Drug Administration has approved AstraZeneca and Avillion’s respiratory drug Airsupra, making it the only rescue medication cleared for as-needed use to reduce risk of asthma exacerbations.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.
• Source: Archive

AstraZeneca PLC's asthma rescue medication Airsupra has received the green light from US regulators, boosting the UK major's respiratory franchise which is feeling the pinch due to declining revenues of the blockbuster Symbicort.

The US Food and Drug Administration has approved Airsupra, which has been developed with Avillion LLP, making it the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category